Streetbeat News

Earnings

BIIB

ESALY

NVS

Biogen Inc (NASDAQ:BIIB) reported Q4 2023 sales of $2.39 billion, missing estimates and showing a 6% Y/Y decline. Adjusted EPS also fell by 27%. The company's partner, Eisai Co Ltd (OTC:ESALY), faces delays with Leqembi's patient enrollment, impacting Biogen's stock growth. Baird analyst lowered Biogen's price target to $316 from $333 but maintained an Outperform rating. Competition in Spinal Muscular Atrophy treatments from Novartis AG (NYSE:NVS) and Roche's Genentech affects Biogen's Spinraza. Biogen may pursue $1B-$2B deals to fill revenue gaps, focusing on the CNS space.

Portfolio Pulse from Vandana Singh

February 14, 2024 | 8:11 pm

GAU

Galiano Gold (AMEX:GAU) is expected to report an EPS of $0.02 in its upcoming quarterly earnings on February 15, 2024. Analysts and investors are looking for an earnings beat and positive guidance for future growth. Galiano Gold's stock performance has been positive over the last year, with shares up 59.56%, indicating bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 8:02 pm

PTN

Palatin Techs (AMEX:PTN) is scheduled to release its quarterly earnings report on February 15, 2024, with an estimated EPS of $-0.20. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, PTN's stock price has shown sensitivity to both earnings outcomes and forward guidance. Last quarter, PTN missed its EPS estimate, resulting in a 3.65% increase in share price the following day. Over the past year, PTN shares have risen by 39.62%, indicating a bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 8:02 pm

TTOO

T2 Biosystems (NASDAQ:TTOO) is scheduled to release its quarterly earnings report on February 15, 2024, with an expected EPS of $-2.22. Analysts and investors will be closely watching for not only an earnings beat but also positive guidance for the next quarter. Historical data shows mixed reactions to past earnings reports, with share prices fluctuating post-announcement. Currently, T2 Biosystems shares are trading at $6.24, down 92.37% over the last year, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 8:02 pm

ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) is expected to report a Q4 EPS of $-1.33 on February 15, 2024. Analysts and investors will be looking for positive guidance beyond the earnings beat or miss. The company's past performance shows a mix of earnings beats and misses with corresponding stock price changes. Shares are currently down 25.86% over the last 52 weeks, trading at $162.0 as of February 13.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 8:02 pm

AUPH

Aurinia Pharmaceuticals (NASDAQ:AUPH) is scheduled to release its quarterly earnings report on February 15, 2024, with analysts expecting an EPS of $-0.16. The company's past earnings performance shows a pattern of beating EPS estimates, which has occasionally led to positive stock price movements the following day. Shares of Aurinia Pharmaceuticals were trading at $7.78 as of February 13, with a 3.35% increase over the last 52 weeks. Investors are likely focused on whether the company will beat the EPS estimate and provide positive guidance for future growth.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 8:01 pm

BLZE

Backblaze (NASDAQ:BLZE) is expected to report a Q4 earnings per share (EPS) of $-0.37 on February 15, 2024. Analysts and investors will be looking for the company to beat this estimate and provide positive guidance for the next quarter. Historical data shows mixed reactions to past earnings reports, with share price movements varying post-announcement. Shares are currently trading at $8.05, up 27.26% over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 8:01 pm

UEIC

Universal Electronics (NASDAQ:UEIC) is set to release its quarterly earnings report on February 15, 2024, with an estimated EPS of $-0.01. Analysts and investors will be closely watching for not only an earnings beat but also positive guidance for the next quarter. Historical data shows that UEIC's stock price reacts significantly to earnings performance and guidance. The stock is currently trading at $8.44, down 65.07% over the last 52 weeks, indicating a challenging period for long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 8:01 pm

ED

Consolidated Edison (NYSE:ED) is scheduled to release its quarterly earnings report on February 15, 2024, with an expected EPS of $0.96. Analysts and investors are particularly interested in the company's guidance for future growth. The company's past earnings performance shows a mix of hits and misses against EPS estimates, with minor share price fluctuations following the announcements. Currently, shares are trading at $86.67, marking a 5.19% decline over the last year. This performance trend and the upcoming earnings report are critical for investors.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 8:01 pm

MERC

Mercer Intl (NASDAQ:MERC) is scheduled to release its quarterly earnings report on February 15, 2024, with analysts expecting an EPS of $-0.54. The company's past performance shows a mix of earnings beats and misses, with significant share price movements following the announcements. Shares are currently trading at $7.6, down 34.24% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 8:01 pm